Naiem Issa, MD, PhD

Panelists discuss how new nonsteroidal therapies improve adherence, comfort, and long-term skin health for children with AD.

Panelists discuss how JAK-targeting topical therapies offer effective, well-tolerated solutions for children with mild to moderate AD.

Panelists discuss how evidence from clinical studies supports the safety and effectiveness of new nonsteroidal treatments for children with AD.

Panelists discuss how low systemic absorption and simple dosing schedules improve safety, adherence, and caregiver confidence in pediatric AD care.

Panelists discuss how clinical results confirm the effectiveness, safety, and caregiver convenience of new nonsteroidal therapies for pediatric AD.

Panelists discuss how improved clinical trial design helps ensure new treatments reflect real-world experiences and family priorities.

Panelists discuss how unmet needs in topical care highlight the importance of safe, simple, and effective long-term therapies for children with AD.

Panelists discuss how individualized strategies combining steroids, nonsteroidal agents, and caregiver education promote sustained disease control in children.

Panelists discuss how nonsteroidal PDE-4 and JAK inhibitors offer effective, targeted relief while addressing caregiver concerns about safety and chronic use.

Panelists discuss how calcineurin inhibitors can be safely and effectively used in children with proper education and clinical oversight.

Panelists discuss how corticosteroids remain essential for controlling flares but must be used thoughtfully with education and reassurance for families.

Panelists discuss how individualized, consistent topical care helps build trust, promotes adherence, and prevents disease flare-ups in children with AD.

Panelists discuss how treatment goals should center on the child’s comfort, sleep quality, and emotional well-being, not just visible skin improvement.

Panelists discuss how atopic dermatitis affects not only the child’s comfort and confidence but also family well-being and emotional health.

Panelists discuss their advice for dermatologists managing chronic spontaneous urticaria (CSU), emphasizing the importance of individualized treatment plans, and staying updated on emerging therapies and clinical guidelines.

Panelists discuss the unmet needs in chronic spontaneous urticaria (CSU) management, highlighting the evolution of the field toward more personalized and effective treatment strategies to address refractory symptoms.

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors are reshaping the evolving treatment landscape for chronic spontaneous urticaria (CSU) by providing targeted therapeutic options that address underlying mast cell activation.

Panelists discuss how patient education and shared decision-making are crucial in selecting appropriate therapies, as they empower patients to understand their treatment options and actively participate in their care.

Panelists discuss how Bruton tyrosine kinase’s (BTK) role in mediating mast cell degranulation makes it an ideal target for chronic spontaneous urticaria (CSU) treatment, as inhibiting BTK could effectively reduce histamine release and its associated symptoms.

Panelists discuss how the integration of advanced treatments such as biologics and Bruton tyrosine kinase (BTK) inhibitors can bridge the gap in managing chronic spontaneous urticaria (CSU) for patients unresponsive to antihistamines.

Panelists discuss how steroids can play a role in the management of chronic spontaneous urticaria (CSU), while emphasizing that practitioners should exercise caution due to potential adverse effects and the need for careful monitoring when using systemic steroids.

Panelists discuss how the treatment goals for chronic spontaneous urticaria (CSU) focus on achieving symptom control and improving quality of life for patients, while also aiming for effective management strategies and adherence to treatment plans for physicians.

Panelists discuss how, given that approximately 49% of patients with chronic spontaneous urticaria (CSU) consult general practitioners, while only approximately 19% see dermatologists, there is a compelling case for more patients to be referred to dermatologists, as CSU is an internally driven disease that may benefit from specialized expertise.

Panelists discuss how disease severity in chronic spontaneous urticaria (CSU) is assessed using tools such as the Urticaria Activity Score over 7 days (UAS7) and the Urticaria Control Test (UCT), while also addressing the frequency of delayed diagnoses and the significant implications for condition management and patient quality of life.

Panelists discuss how testing for chronic spontaneous urticaria (CSU) is recommended, with routine blood counts, including tests for erythrocyte sedimentation rate (ESR) and/or c-reactive protein (CRP), and specific antibody tests such as immunoglobulin G (IgG) anti- thyroid peroxidase (TPO) and total immunoglobulin E (IgE) being highlighted, according to guidelines.

Panelists discuss how the diagnosis of chronic spontaneous urticaria (CSU) involves assessing wheals, hives, and angioedema, while emphasizing that the chronic and spontaneous nature of the condition can complicate the diagnostic process.

Panelists discuss how recent insights into chronic spontaneous urticaria (CSU) pathogenesis reveal potential autoimmune responses and highlight the role of Bruton tyrosine kinase (BTK) as a key mediator in mast cell degranulation and histamine release.

Panelists discuss how patients with chronic spontaneous urticaria (CSU) experience increased rates of depression, sleep disturbances, and absenteeism, significantly impacting their professional life and overall quality of life.

Panelists discuss how chronic spontaneous urticaria (CSU) is defined as the spontaneous appearance of wheals or angioedema lasting more than six 6 weeks, which can significantly impact patients' clinical health and psychosocial well-being.

Panelists discuss how chronic spontaneous urticaria (CSU) affects approximately 0.5% to 1% of the population, predominantly impacting women and often presenting with variable wheals and angioedema.